Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of three dose strengths of V181 dengue vaccine in healthy adults
MOH_2022-05-18_010804Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- May 2022
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TetraVax-DV in dengue fever (4 arms), sponsored by Merck & Co. Primary endpoints: Safety of V181 at three dose strengths versus placebo and Tolerability of V181 at three dose strengths versus placebo. Planned start May 2022; status: not yet recruiting.
02
Drugs
TetraVax-DV
03
Conditions
dengue fever
Beyond the preview
Go deeper on MOH_2022-05-18_010804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-18_010804.